One thing that has perhaps received a little less attention than the proposed regulatory reforms to the Patented Medicine Prices Review Board is the significant changes that are happening in the health portfolio around how drugs are reviewed and approved. A key objective is to streamline and make it faster for valuable new medicines to get to market. We're working quite closely with the industry on that. I'll just give you an example.
We want to provide new pathways to market that might rely more extensively on reviews that take place in other jurisdictions. If a new drug comes out, and it's clear it has tremendous benefits for patients—maybe it saves the health system money—if our major partners abroad have already reviewed and approved it, we're looking at whether we could use that as a basis to expedite getting it to market. Industry is very interested in some of these new regulatory pathways. While pricing, obviously and understandably, is getting a lot of attention, we're doing a lot of other things to try to make it easier and faster for valuable medication to make it onto the Canadian market.